872511-32-5

Usage

Uses

Used in the Production of Polyurethane Foams:
Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxyis used as a key chemical intermediate for the production of polyurethane foams. It contributes to the formation of the foam's structure and properties, enhancing its durability and performance in various applications.
Used in Adhesives:
Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxyis also utilized as a component in the formulation of adhesives. Its chemical structure allows it to improve the bonding strength and flexibility of the adhesives, making them suitable for a wide range of uses.
Used in Coatings:
Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxyis used in the development of coatings, where it plays a role in enhancing the durability, adhesion, and resistance properties of the coatings. This makes the coatings more effective in protecting surfaces from various environmental factors.
Used in Chemical Synthesis:
In the chemical industry, Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxyserves as a versatile intermediate for the synthesis of various other chemicals and compounds, expanding its applications across different sectors.

Upstream product

• 75-44-5 phosgene 
• 872509-56-3 2,6-dichloro-3,5-dimethoxy-phenylamine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 10272-07-8 3.5-dimethoxyaniline 
• 79257-61-7 N-(3,5-dimethoxy-phenyl)-acetamide 
• 943189-21-7 N-(2,6-dichloro-3,5-dimethoxy-phenyl)-acetamide 

Downstream Products

• 1802253-30-0 1-(6-chloropyrimidin-4-yl)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylurea 

Relevant academic research and scientific papers

Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2

Aberrant activation of FGFR signaling occurs in many cancers, and ATP-competitive FGFR inhibitors have received regulatory approval. Despite demonstrating clinical efficacy, these inhibitors exhibit dose-limiting toxicity, potentially due to a lack of selectivity amongst the FGFR family and are poorly tolerated. Here, we report the discovery and characterization of DGY-09-192, a bivalent degrader that couples the pan-FGFR inhibitor BGJ398 to a CRL2VHL E3 ligase recruiting ligand, which preferentially induces FGFR1&2 degradation while largely sparing FGFR3&4. DGY-09-192 exhibited two-digit nanomolar DC50s for both wildtype FGFR2 and several FGFR2-fusions, resulting in degradation-dependent antiproliferative activity in representative gastric cancer and cholangiocarcinoma cells. Importantly, DGY-09-192 induced degradation of a clinically relevant FGFR2 fusion protein in a xenograft model. Taken together, we demonstrate that DGY-09-192 has potential as a prototype FGFR degrader.

DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2)

The present invention relates to bispecific compounds, compositions, and methods for treating diseases or conditions characterized or mediated by aberrant fibroblast growth factor receptor 2 (FGFR2) activity.

FGFR4 inhibitor and application thereof

The invention belongs to the field of medical chemistry, and particularly relates to a novel FGFR4 inhibitor, a medicine composition comprising the inhibitor and a use of the inhibitor or medicine composition as a cancer curative drug.

HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR

A heterocyclic compound is described, which is an inhibitor of FGFR (fibroblast growth factor receptor). Specifically, it is a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a p

A model used for fibroblast growth factor receptor inhibitors and use thereof (by machine translation)

The invention belongs to the field of medical technology, in particular of formula (I) indicated by the fibroblast growth factor receptor 4 (FGFR4) irreversible inhibitors, their pharmaceutically acceptable salt, compound solvent, polymorphs and tautomeri

FGFR4 INHIBITORS

We provide FGFR inhibitors, their salts, methods of manufacture, and methods of use.

CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt

PYRIMIDINE FGFR4 INHIBITORS

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

A novel series of N-aryl-N′-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the b

PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS

The invention relates to heteroaryl aryl ureas of the formula (IA), wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.